ARTICLE | Emerging Company Profile
Sherlock: Leveraging CRISPR, synthetic biology for diagnostics
How Sherlock is leveraging CRISPR gene editing, synthetic biology to rapidly and accurately detect disease
June 14, 2019 10:14 PM UTC
By taking advantage of two hot technologies, Sherlock is developing a pair of molecular diagnostics that can be used alone or together to rapidly and accurately detect disease in a wide variety of applications.
Sherlock Biosciences Inc. launched in March with $35 million in funding and exclusive licenses to a CRISPR-based diagnostic from Feng Zhang's lab at the Broad Institute of MIT and Harvard and a synthetic biology platform from Jim Collins' team at Harvard University, both pioneers in their fields...